NGM Biopharmaceuticals Inc (NASDAQ:NGM)
| 14.96 Delayed Data As of 4:00pm ET |  -0.32 / -2.09%Today’s Change | 14.90 Today|||52-Week Range 32.12 | -15.53% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $1.2B |
Company Description
NGM Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutics for cardio-metabolic, liver, oncologic, and ophthalmic diseases. Its lead product candidate, aldafermin, is designed for the treatment of patients with non-alcoholic steatohepatitis, with liver fibrosis stage 2, 3, or 4. The company was founded by Jin-Long Chen on December 20, 2007 and is headquartered in South San Francisco, CA.
Contact Information
NGM Biopharmaceuticals, Inc. 333 Oyster Point Boulevard South San Francisco California 94080-7014 |
Employees
Shareholders
| Individual stakeholders | 25.02% |
| Other institutional | 16.74% |
| Mutual fund holders | 11.12% |
Top Executives
| David J. Woodhouse | Chief Executive Officer & Director |
| Siobhan Nolan Mangini | CFO & Principal Accounting Officer |
| Jin-Long Chen | Director & Chief Scientific Officer |
| Hui Tian | Vice President-Research |
| Marc Learned | Vice President-Research Operations |
